A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Trial Profile

A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Levonorgestrel (Primary)
  • Indications Pregnancy
  • Focus Registrational; Therapeutic Use
  • Acronyms ACCESS IUS
  • Sponsors Medicines360
  • Most Recent Events

    • 30 Apr 2018 Results assessing five-year efficacy and safety data for Liletta, were presented at the 66th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
    • 30 Apr 2018 According to an Allergan media release, five-year data presented at the American College of Obstetricians and Gynecologists (ACOG) 2018 annual clinical and scientific meeting.
    • 30 Apr 2018 Five-years results presented in a Medicines360 media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top